The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The oral drug, Zenrelia, is to control pruritus, or itching, associated with allergic dermatitis and control of atopic ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

The transaction, valued at $1.2 billion, is seen as a positive benchmark for Arcutis, especially considering the promising performance of its product Zoryve in treating psoriasis, atopic dermatitis, ...

Roflumilast cream 0.15% was well tolerated and significantly improved symptoms in adults and children with mild to moderate atopic dermatitis (AD) in two phase 3 trials. The two phase 3 randomized ...

The study exposures included genetic estimators of stroke, CAD, psoriasis, and nine additional IMIDs. These included asthma, ...

Panelists discuss how type 2 inflammatory diseases, such as asthma, atopic dermatitis, and chronic rhinosinusitis, can significantly impair patients’ quality of life through persistent symptoms and ...

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...